SG11201909443YA - Compounds and methods for treating bacterial infections - Google Patents
Compounds and methods for treating bacterial infectionsInfo
- Publication number
- SG11201909443YA SG11201909443YA SG11201909443YA SG11201909443YA SG 11201909443Y A SG11201909443Y A SG 11201909443YA SG 11201909443Y A SG11201909443Y A SG 11201909443YA SG 11201909443Y A SG11201909443Y A SG 11201909443YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- waltham
- drive
- compounds
- gatehouse
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 235000018185 Betula X alpestris Nutrition 0.000 abstract 1
- 235000018212 Betula X uliginosa Nutrition 0.000 abstract 1
- 241000269333 Caudata Species 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502867P | 2017-05-08 | 2017-05-08 | |
| PCT/US2018/031593 WO2018208769A1 (en) | 2017-05-08 | 2018-05-08 | Compounds and methods for treating bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909443YA true SG11201909443YA (en) | 2019-11-28 |
Family
ID=62223332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909443Y SG11201909443YA (en) | 2017-05-08 | 2018-05-08 | Compounds and methods for treating bacterial infections |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11046694B2 (enExample) |
| EP (1) | EP3630111B1 (enExample) |
| JP (1) | JP7058322B2 (enExample) |
| KR (1) | KR102611447B1 (enExample) |
| CN (1) | CN110709081B (enExample) |
| AU (1) | AU2018266640B2 (enExample) |
| CA (1) | CA3059773A1 (enExample) |
| CY (1) | CY1125340T1 (enExample) |
| DK (1) | DK3630111T3 (enExample) |
| EA (1) | EA038393B1 (enExample) |
| ES (1) | ES2907858T3 (enExample) |
| HR (1) | HRP20220231T1 (enExample) |
| HU (1) | HUE057592T2 (enExample) |
| IL (1) | IL270380B (enExample) |
| LT (1) | LT3630111T (enExample) |
| MA (1) | MA48743A (enExample) |
| MX (1) | MX385203B (enExample) |
| MY (1) | MY201377A (enExample) |
| PE (1) | PE20200333A1 (enExample) |
| PH (1) | PH12019502509A1 (enExample) |
| PL (1) | PL3630111T3 (enExample) |
| PT (1) | PT3630111T (enExample) |
| SG (1) | SG11201909443YA (enExample) |
| SI (1) | SI3630111T1 (enExample) |
| SM (1) | SMT202200110T1 (enExample) |
| TW (1) | TWI791018B (enExample) |
| WO (1) | WO2018208769A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3833665T3 (da) | 2018-08-09 | 2023-10-09 | Antabio Sas | Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| CN111675641B (zh) * | 2020-06-04 | 2023-09-08 | 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） | 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法 |
| EP4146651A4 (en) | 2021-05-07 | 2024-06-05 | Ningxia Academy of Agriculture and Forestry Sciences | SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS |
| US11814385B2 (en) | 2021-06-25 | 2023-11-14 | University Of South Florida | Small molecule inhibitors targeting Clostridioides difficile sporulation |
| WO2025064681A1 (en) * | 2023-09-19 | 2025-03-27 | Entasis Therapeutics Inc. | Compounds and methods for treating bacterial infections |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995018129A1 (en) | 1993-12-29 | 1995-07-06 | Pfizer Inc. | Diazabicyclic neurokinin antagonists |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2825705B1 (fr) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2848210B1 (fr) * | 2002-12-06 | 2007-10-19 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases |
| US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| US7507727B2 (en) * | 2003-04-07 | 2009-03-24 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs and methods of using thereof |
| FR2914923B1 (fr) | 2007-04-12 | 2013-06-14 | Novexel | Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens. |
| JP5038509B2 (ja) | 2008-01-18 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | β−ラクタマーゼ阻害剤 |
| FR2930553B1 (fr) | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
| EP2135959A1 (en) | 2008-06-19 | 2009-12-23 | Novexel | Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
| FR2936798B1 (fr) | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
| FR2936951B1 (fr) | 2008-10-10 | 2010-12-03 | Novexel | Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments |
| FR2937034B1 (fr) * | 2008-10-10 | 2012-11-23 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens |
| FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| AU2011373912B2 (en) | 2011-07-26 | 2016-09-29 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| JP5808860B2 (ja) | 2011-07-26 | 2015-11-10 | ウォックハート リミテッド | スルバクタム及びベータ−ラクタマーゼインヒビターを含む医薬組成物 |
| RU2636147C1 (ru) | 2011-08-27 | 2017-11-21 | Вокхардт Лимитед | Производные 1,6-диазабицикло[3,2,1]октан-7-она и их применение при лечении бактериальных инфекционных болезней |
| AU2012303693B2 (en) * | 2011-08-30 | 2014-07-03 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections |
| US8754102B2 (en) | 2011-09-13 | 2014-06-17 | Wockhardt Ltd. | Nitrogen containing compounds and their use |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
| AU2013237869A1 (en) | 2012-03-30 | 2014-10-23 | Cubist Pharmaceuticals, Inc. | Isoxazole beta-lactamase inhibitors |
| US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2013149121A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
| AR090539A1 (es) | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
| TWI565707B (zh) | 2012-05-30 | 2017-01-11 | 明治製菓藥業股份有限公司 | 新穎β－內醯胺酶抑制劑及其製造方法 |
| EP2961751B1 (en) | 2012-08-25 | 2018-03-21 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections |
| CN104768547A (zh) | 2012-09-03 | 2015-07-08 | 沃克哈特有限公司 | 抗菌组合物 |
| CA2897446A1 (en) | 2013-02-06 | 2014-08-14 | Astrazeneca Ab | Combination therapy for the treatment of nosocomial pneumonia |
| WO2014141132A1 (en) * | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
| US9968593B2 (en) | 2014-11-17 | 2018-05-15 | Entasis Therapeutics Limited | Combination therapy for treatment of resistant bacterial infections |
| SMT202200397T1 (it) | 2016-09-16 | 2022-11-18 | Entasis Therapeutics Ltd | Composti inibitori di beta-lattamasi |
-
2018
- 2018-05-08 PT PT187267026T patent/PT3630111T/pt unknown
- 2018-05-08 TW TW107115559A patent/TWI791018B/zh active
- 2018-05-08 IL IL270380A patent/IL270380B/en unknown
- 2018-05-08 HR HRP20220231TT patent/HRP20220231T1/hr unknown
- 2018-05-08 SI SI201830571T patent/SI3630111T1/sl unknown
- 2018-05-08 SG SG11201909443Y patent/SG11201909443YA/en unknown
- 2018-05-08 HU HUE18726702A patent/HUE057592T2/hu unknown
- 2018-05-08 PE PE2019002309A patent/PE20200333A1/es unknown
- 2018-05-08 PL PL18726702T patent/PL3630111T3/pl unknown
- 2018-05-08 CN CN201880030289.8A patent/CN110709081B/zh active Active
- 2018-05-08 EP EP18726702.6A patent/EP3630111B1/en active Active
- 2018-05-08 WO PCT/US2018/031593 patent/WO2018208769A1/en not_active Ceased
- 2018-05-08 US US16/611,065 patent/US11046694B2/en active Active
- 2018-05-08 CA CA3059773A patent/CA3059773A1/en active Pending
- 2018-05-08 AU AU2018266640A patent/AU2018266640B2/en active Active
- 2018-05-08 MY MYPI2019006163A patent/MY201377A/en unknown
- 2018-05-08 DK DK18726702.6T patent/DK3630111T3/da active
- 2018-05-08 MX MX2019013291A patent/MX385203B/es unknown
- 2018-05-08 ES ES18726702T patent/ES2907858T3/es active Active
- 2018-05-08 KR KR1020197035865A patent/KR102611447B1/ko active Active
- 2018-05-08 SM SM20220110T patent/SMT202200110T1/it unknown
- 2018-05-08 JP JP2020512769A patent/JP7058322B2/ja active Active
- 2018-05-08 LT LTEPPCT/US2018/031593T patent/LT3630111T/lt unknown
- 2018-05-08 EA EA201992370A patent/EA038393B1/ru unknown
- 2018-05-08 MA MA048743A patent/MA48743A/fr unknown
-
2019
- 2019-11-08 PH PH12019502509A patent/PH12019502509A1/en unknown
-
2022
- 2022-02-23 CY CY20221100157T patent/CY1125340T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909443YA (en) | Compounds and methods for treating bacterial infections | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201810834WA (en) | Hepatitis b antiviral agents | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201901658PA (en) | Beta-lactamase inhibitor compounds | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| SG11201901457TA (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201811161YA (en) | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme | |
| SG11201407674TA (en) | D-amino acid compounds for liver disease | |
| SG11201906417RA (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors | |
| SG11201900689RA (en) | Compounds and compositions and uses thereof | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201804721SA (en) | Modulators of complement activity | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201903348UA (en) | Therapeutic compounds and methods of use thereof |